Medicines and Healthcare Products Regulatory Agency: Corporate Plan 2023 to 2026

The MHRA has released its four strategic priorities over the next three years:

1. Maintain public trust through transparency and proactive communication

2. Enable healthcare access to safe and effective medical products

3. Deliver scientific and regulatory excellence through strategic partnerships

4. Become an agency where people flourish alongside a responsive customer service culture

Exciting news about the new the Yellow Card biobank “to identify genetic factors in patients who have suffered side effects, enabling more targeted approaches to minimise harm and by informing future drug development approaches.”

https://www.gov.uk/government/publications/mhra-corporate-plan-2023-to-2026/medicines-and-healthcare-products-regulatory-agency-corporate-plan-2023-to-2026